Copernicus Therapeutics, Inc. To Receive Continued Support From Cystic Fibrosis Foundation Therapeutics, Inc. To Further Develop Non-Viral Gene Therapy For Cystic Fibrosis
Published: Feb 14, 2006
CLEVELAND--(BUSINESS WIRE)--Feb. 14, 2006--Copernicus Therapeutics, Inc. announced today it had reached an agreement with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) whereby CFFT will continue to fund development of Copernicus' potential gene therapy for cystic fibrosis (CF). The agreement provides $1.5 million for 2006 with the potential for $4.6 million in additional funding for 2007 if satisfactory progress continues. The research plan included in the agreement anticipates that if satisfactory progress continues in 2007, CFFT will support Copernicus' CF gene therapy development and clinical programs through completion of a multiple dose phase II clinical trial. Copernicus' unique, non-viral nanoparticle formulation is intended to deliver a normal copy of the CF gene to the affected lung cells of CF patients, and may provide a therapy that treats the root cause of CF. Copernicus' first clinical trial, supported by CFFT, demonstrated the desired safety profile and encouraging biological improvements were observed.